Full Press Release Details
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference.
IRD
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Key Takeaway: Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy